The use of antimicrobial agents in COVID-19 and infections: what we know
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/7245 |
Resumo: | Today, COVID-19 is causing a worrisome public health emergency and mortality is rising rapidly around the world. At the current time of the pandemic, although there has been much persistence in diagnosing several patients with symptoms or close contacts, there are no definitive guidelines for the initial therapeutic approach for them and, therefore, many patients are dying from a hyperinflammatory immune reaction labeled a "cytokine storm". The use of antimicrobials in the treatment and prevention of COVID-19, caused by the new SARS-CoV-2 coronavirus, is on the rise. Antibiotics used to treat staphylococcal infection, previously showed efficacy to inhibit the first stage of MERScoronarivus viral cycle in human cells. This activity is conserved in SARS-Cov-2, placing its use as a potential treatment for patients with this virus. A literature review using the PubMed, LILACS and Scielo databases was performed, with the terms "Covid", "antibiotic, "therapy" and "microbial resistance" and equivalents in English. In this review, we discussed some important points dedicated to the management of patients with COVID-19 using antibiotics. |
id |
UNIFEI_4ae690c748f9b76838f3591b81dccd7b |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/7245 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
The use of antimicrobial agents in COVID-19 and infections: what we knowEl uso de agentes antimicrobianos en COVID-19 y infecciones: lo que sabemosO uso de antimicrobiano na COVID-19 e as infecções: o que sabemosAntibioticoCovidInfecção. AntibióticoCovidInfección.AntibioticCovidInfection.Today, COVID-19 is causing a worrisome public health emergency and mortality is rising rapidly around the world. At the current time of the pandemic, although there has been much persistence in diagnosing several patients with symptoms or close contacts, there are no definitive guidelines for the initial therapeutic approach for them and, therefore, many patients are dying from a hyperinflammatory immune reaction labeled a "cytokine storm". The use of antimicrobials in the treatment and prevention of COVID-19, caused by the new SARS-CoV-2 coronavirus, is on the rise. Antibiotics used to treat staphylococcal infection, previously showed efficacy to inhibit the first stage of MERScoronarivus viral cycle in human cells. This activity is conserved in SARS-Cov-2, placing its use as a potential treatment for patients with this virus. A literature review using the PubMed, LILACS and Scielo databases was performed, with the terms "Covid", "antibiotic, "therapy" and "microbial resistance" and equivalents in English. In this review, we discussed some important points dedicated to the management of patients with COVID-19 using antibiotics.Hoy en día, el COVID-19 está causando una preocupante emergencia de salud pública y la mortalidad está aumentando rápidamente en todo el mundo. En el momento actual de la pandemia, aunque ha habido mucha persistencia en el diagnóstico de varios pacientes con síntomas o contactos cercanos, no hay directrices definitivas sobre el enfoque terapéutico inicial para ellos y, por lo tanto, muchos pacientes están muriendo de una reacción inmunológica hiperinflamatoria etiquetada como "tormenta de citoquinas". El uso de antimicrobianos en el tratamiento y la prevención de los COVID-19, causados por el nuevo coronavirus del SARS-CoV-2, está aumentando. Los antibióticos utilizados para tratar la infección por estafilococos, anteriormente mostraron eficacia para inhibir la primera etapa del ciclo viral del MERScoronarivus en las células humanas. Esta actividad se conserva en el SARS-Cov-2, lo que hace que se utilice como posible tratamiento para los pacientes con este virus. Se realizó una revisión de la literatura utilizando las bases de datos PubMed, LILACS y Scielo, con los términos "Covid", "antibiotic", "therapy" y "microbial resistance" y sus equivalentes en inglés. En esta revisión, discutimos algunos puntos importantes dedicados al manejo de pacientes con COVID-19 usando antibióticos.Atualmente, o COVID-19 está ocasionando uma preocupante emergência de saúde pública e a mortalidade está aumentando rapidamente em todo o mundo. No momento atual da pandemia, apesar de ter havido muita persistencia para diagnosticar vários pacientes com sintomas ou contatos próximos, não existe diretrizes definitivas para a abordagem terapêutica inicial para eles e, portanto, muitos pacientes estão morrendo devido a uma reação imunológica hiperinflamatória rotulado como "tempestade de citocinas".O uso de antimicrobianos no tratamento e prevenção de COVID-19, causado pelo novo coronavírus SARS-CoV-2, está em ascensão.Antibióticos usado para tratar infecção por estafilococos, anteriormente mostrou eficácia para inibir o primeiro estágio do ciclo viral do MERScoronarivus em células humanas. Essa atividade é conservada no SARS-Cov-2, colocando esse emprego como um tratamento potencial para pacientes com esse vírus. Foi realizado uma revisão da literatura utilizando os bancos de dados PubMed, LILACS e Scielo, com os termos “Covid”, “antibiotico, “terapia “e “resistencia microbiana e equivalentes em inglês. Nesta revisão, discutimos alguns pontos importantes dedicados ao manejo de pacientes com COVID-19 em uso de antibioticos.Research, Society and Development2020-09-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/724510.33448/rsd-v9i9.7245Research, Society and Development; Vol. 9 No. 9; e841997245Research, Society and Development; Vol. 9 Núm. 9; e841997245Research, Society and Development; v. 9 n. 9; e8419972452525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/7245/7107Copyright (c) 2020 Patricia Oliveira Vellano; Maykon Jhuly Martins de Paivahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessVellano, Patricia Oliveira Paiva, Maykon Jhuly Martins de2020-09-18T01:42:11Zoai:ojs.pkp.sfu.ca:article/7245Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:30:02.069378Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
The use of antimicrobial agents in COVID-19 and infections: what we know El uso de agentes antimicrobianos en COVID-19 y infecciones: lo que sabemos O uso de antimicrobiano na COVID-19 e as infecções: o que sabemos |
title |
The use of antimicrobial agents in COVID-19 and infections: what we know |
spellingShingle |
The use of antimicrobial agents in COVID-19 and infections: what we know Vellano, Patricia Oliveira Antibiotico Covid Infecção. Antibiótico Covid Infección. Antibiotic Covid Infection. |
title_short |
The use of antimicrobial agents in COVID-19 and infections: what we know |
title_full |
The use of antimicrobial agents in COVID-19 and infections: what we know |
title_fullStr |
The use of antimicrobial agents in COVID-19 and infections: what we know |
title_full_unstemmed |
The use of antimicrobial agents in COVID-19 and infections: what we know |
title_sort |
The use of antimicrobial agents in COVID-19 and infections: what we know |
author |
Vellano, Patricia Oliveira |
author_facet |
Vellano, Patricia Oliveira Paiva, Maykon Jhuly Martins de |
author_role |
author |
author2 |
Paiva, Maykon Jhuly Martins de |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Vellano, Patricia Oliveira Paiva, Maykon Jhuly Martins de |
dc.subject.por.fl_str_mv |
Antibiotico Covid Infecção. Antibiótico Covid Infección. Antibiotic Covid Infection. |
topic |
Antibiotico Covid Infecção. Antibiótico Covid Infección. Antibiotic Covid Infection. |
description |
Today, COVID-19 is causing a worrisome public health emergency and mortality is rising rapidly around the world. At the current time of the pandemic, although there has been much persistence in diagnosing several patients with symptoms or close contacts, there are no definitive guidelines for the initial therapeutic approach for them and, therefore, many patients are dying from a hyperinflammatory immune reaction labeled a "cytokine storm". The use of antimicrobials in the treatment and prevention of COVID-19, caused by the new SARS-CoV-2 coronavirus, is on the rise. Antibiotics used to treat staphylococcal infection, previously showed efficacy to inhibit the first stage of MERScoronarivus viral cycle in human cells. This activity is conserved in SARS-Cov-2, placing its use as a potential treatment for patients with this virus. A literature review using the PubMed, LILACS and Scielo databases was performed, with the terms "Covid", "antibiotic, "therapy" and "microbial resistance" and equivalents in English. In this review, we discussed some important points dedicated to the management of patients with COVID-19 using antibiotics. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-09-09 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/7245 10.33448/rsd-v9i9.7245 |
url |
https://rsdjournal.org/index.php/rsd/article/view/7245 |
identifier_str_mv |
10.33448/rsd-v9i9.7245 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/7245/7107 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2020 Patricia Oliveira Vellano; Maykon Jhuly Martins de Paiva https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2020 Patricia Oliveira Vellano; Maykon Jhuly Martins de Paiva https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 9 No. 9; e841997245 Research, Society and Development; Vol. 9 Núm. 9; e841997245 Research, Society and Development; v. 9 n. 9; e841997245 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052656693280768 |